EDVP Parallax Health Sciences

Parallax Health Sciences Announces Licensing Agreement With HealthPointe Solutions 

Parallax Health Sciences Announces Licensing Agreement With HealthPointe Solutions 





Cognitive Artificial Intelligence and Data Analytics Combined with Outcomes Optimization for the Healthcare Market

SANTA MONICA, CA, July 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Parallax Health Sciences, Inc. (OTCQB: PRLX) (“Parallax” or the “Company”), an outcome-driven connected healthcare company, today announces it has entered into a strategic license agreement with HealthPointe Solutions, a provider of health and wellness solutions powered by cognitive artificial intelligence, (“Cognitive AI”).  HealthPointe’s Cognitive AI solutions powers understanding across a wide variety of healthcare analytics and driving value-based outcomes.

Mark Anderson, HealthPointe Solutions, Inc. President and Chief Operating Officer, states, “Our collaboration with Parallax Health Sciences will bring a new age of behavior modification toolkits for population and digital health allowing better collaboration between physicians and their patients while driving treatment compliance, digital monitoring, and better outcomes to reduce the burden of illness for the populations we engage.  We are truly excited about our opportunity to help transform the healthcare landscape together.” 

Nathaniel Bradley, Parallax Health Sciences, Inc. Chief Technology Officer, stated, “We chose HealthPointe Solutions because of their senior management’s deep background in healthcare and healthcare technologies.”  Mr. Bradley continued, “HealthPointe Solutions provides us with a broad menu of tools to deliver the solutions that are core to our product offerings.  HealthPointe Solutions focus is on ‘Cognitive Intelligence’ which is right in line with our vision of the future of artificial intelligence.  The Cognitive AI platform provided by HealthPointe Solutions combines the complex nature of healthcare data extraction, management and analysis, coupled with our need for seamless interoperability of applications and technologies and strong security at all points of our services and allows our team to focus on the solutions most important to our customers.”

Paul Arena, Parallax Health Sciences, Inc., Chief Executive Officer, stated, “HealthPointe Solutions is powered by Cyc, the worlds longest-lived artificial intelligence platform, and other advance Artificial Intelligence engines and knowledge bases in turn making HealthPointe Solutions the ideal partner to integrate with the Parallax Care Platform.  HealthPointe Solutions shares our mission to reduce costs, increase access, and improve outcomes for patients and allow providers to deliver better outcomes.”

About HealthPointe Solutions

HealthPointe’s mission is to improve the health and well-being of consumers, through modernizing practitioner and consumer interactions with the power of true Cognitive Artificial Intelligence. HPS’ Cognitive AI is the next generation of AI, a technology developed over 35 years at a cost of hundreds of millions of dollars. The HPS Health Cloud leverages a comprehensive medical and wellness knowledge base, which support shared decisions, to solve healthcare’s most difficult challenges.  For more information, please visit 

About Parallax Health Sciences 

Parallax Health Sciences is an advanced technology, outcome-driven telehealth company that allows for cost-effective remote diagnosis, treatment and monitoring of patients through proprietary platforms of integrated products and services. The Company's interoperable novel applications provide patients point-of-care testing and monitoring with information communicated via internet-based mobile phone applications that are agnostic as to operating system and are built on highly sophisticated data analytics. Information is retrieved real-time by physicians who are monitoring patients with chronic diseases or through biometric feedback for health-related behavior modification, and is automated for integration into electronic health records. The Company's products and offerings capitalize on the digital transformation in healthcare for improved patient compliance, diagnosis and treatment, and support healthcare system cost savings and efficiencies. For more information, please visit   or .

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our Form 10-K and other reports filed with the SEC. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:



Paul Arena

cell 404-915-8449

EN
18/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Parallax Health Sciences

 PRESS RELEASE

Parallax Health Sciences Announces Increased Customer Acquisition in B...

Parallax Health Sciences Announces Increased Customer Acquisition in Both Management and Diagnostics Divisions Company Receives Over $10 million of Telehealth and Medical Supply Contracts from Coast to Coast  NEW YORK, NY, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Parallax Health Sciences, Inc. (OTCQB: PRLX) (“Parallax” or the “Company”), an outcome-driven connected healthcare company, today announced that its Parallax Health Management and Parallax Diagnostics divisions have added customer accounts within the U.S. healthcare industry.  Contracts from home healthcare, ...

 PRESS RELEASE

Parallax Diagnostics Partners with CURE Pharmaceuticals to Distribute ...

Parallax Diagnostics Partners with CURE Pharmaceuticals to Distribute Individually Sealed CUREfilm® D for Medical and Critical Services Workers  COVID-19 Coronavirus Infection Risk May be Reduced by Weekly Dose of Vitamin D3 NEW YORK, NY, April 07, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Parallax Health Sciences, Inc. (OTCQB: PRLX) (“Parallax” or the “Company”), announced that its wholly owned subsidiary Parallax Diagnostics, Inc. has contracted with CURE Pharmaceutical Holding Corp. to distribute CUREfilm® D. The supplement that provides a single wrapped CUREfilm® that de...

 PRESS RELEASE

Parallax Announces International Medical Supply Chain Agreement for CO...

Parallax Announces International Medical Supply Chain Agreement for COVID-19 Testing Kits and FDA Registered Suppliers of Personal Protective Equipment (PPE) Joint Venture Procures from Established Manufacturers with Reliable Supply and Logistics for US Medical Operations NEW YORK, NY, March 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced its wholly-owned subsidiary, Parallax Diagnostics, Inc., has executed a joint venture agreement with the Un...

 PRESS RELEASE

Parallax Launches Secure Good Health Outcomes Telehealth Application f...

Parallax Launches Secure Good Health Outcomes Telehealth Application for Immediate Free Download Parallax Announces Patented Telehealth Initiative to Help Healthcare Providers Better Communicate with Their Patients and Reduce ER Admissions NEW YORK, NY, March 25, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced that its Good Health OutcomesTM Telehealth, diagnostic and Remote Patient Monitoring Mobile App is available for immediate download at zer...

 PRESS RELEASE

Parallax Updates Progress on Proprietary COVID-19 Rapid Test

Parallax Updates Progress on Proprietary COVID-19 Rapid Test Parallax Acquired Antigen And Antibodies Of COVID-19 Being Integrated Into Its Patented And FDA Approved Target Diagnostics Test Platform NEW YORK, New York, March 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced that it has selected the antigens and antibodies that it will use as the markers for its rapid Coronavirus (“COVID-19”) screen test used on its FDA Cleared & Patented Target Di...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch